Idsk -- The approval of dasatinib, an oral kinase inhibitor, has been expanded to include the initial treatment of Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia (Ph+ CP-CML), the Food and Drug Administration announced on Oct. 28.
